Condition: Pheochromocytoma · Paraganglioma · Sponsor: Radboud University Medical Center
In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with and without a hereditary predisposition. The investigators also want to see how the immune system changes during the development of the tumor in people with a hereditary predisposition. Finally, the investigators will compare the data with a control group of people without these tumors. Ultimately, the investigators hope that the results will contribute to the discovery of new immune system-targeted medications for pheochromocytoma and paraganglioma.
This description comes directly from the study's public registry record.
Kai Xu, M.D. · +316 42385270 · kai.xu@radboudumc.nl
Marieke de Laat, M.D. PhD · +3124 361 4599 · marieke.delaat@radboudumc.nl
Always discuss trial participation with your own doctor first.
| Radboudumc | Nijmegen, Gelderland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06444607